Madrigal Pharmaceuticals Secures GalNAc-siRNA License with Arrowhead as Rezdiffra Hits Blockbuster Sales

A GalNAc-conjugated siRNA asset targeting the PNPLA3 gene mutation now sits inside Madrigal Pharmaceuticals' pipeline, raising immediate questions for CDMOs and manufacturing operations already navigating the technical demands of oligonucleotide conjugate production. The licensing agreement with Arrowhead Pharmaceuticals for global rights to ARO-PNPLA3, announced May 5, 2026, adds a clinically validated modality to a franchise that generated $311.3 million in Rezdiffra net sales during Q1 2026 alone, a 127% year-over-year increase.

ARO-PNPLA3 targets patients homozygous for the PNPLA3 I148M mutation, a genotype highly prevalent among Hispanic patients and present in approximately 30% of those with moderate-to-advanced fibrosis (F2–F3). Phase 1 data showed up to a 46% reduction in liver fat by MRI-PDFF at 12 weeks following a single dose at the highest tested level. For process development teams, a single-dose subcutaneous GalNAc-siRNA with that magnitude of effect signals a manufacturing profile distinct from the daily oral small-molecule paradigm Rezdiffra established, different conjugation chemistry, cold-chain considerations, and batch release testing requirements will apply.

The siRNA build is broader than one asset. In February 2026, Madrigal added six preclinical siRNA programs targeting genetically defined MASH subpopulations, positioning the company for combination regimens that pair genetic precision with Rezdiffra's established thyroid hormone receptor-beta mechanism. Each program represents a separate technology transfer and analytical method development workstream for any CDMO partner brought into the supply chain.

On the small-molecule side, the oral GLP-1 candidate MGL-2086 remains on track for Phase 1 initiation in Q2 2026, and an ervogastat/resmetirom drug-drug interaction study is scheduled to start in Q4 2026. The DDI study carries direct relevance for QA and regulatory teams managing combination product dossiers: 21 CFR Part 312 IND amendments and ICH E7/E14 considerations will need to be addressed before any fixed-dose combination pathway is viable.

Madrigal reported $817.9 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2026, providing the financial runway to advance multiple modalities simultaneously. Intellectual property protection for Rezdiffra is expected to extend into 2045, giving the commercial manufacturing base a long planning horizon. With more than 42,250 patients on therapy, up 2.5x from Q1 2025, commercial-scale demand for resmetirom continues to grow, and supply assurance programs will need to pace accordingly.

The ARO-PNPLA3 Phase 2 design and the six preclinical siRNA programs' advancement timelines will be the next measurable checkpoints for operations and regulatory teams tracking Madrigal's manufacturing readiness across modalities.

Source: Madrigal Pharmaceuticals, Inc. via GlobeNewswire, May 6, 2026. Company conference call held May 6, 2026, at 8 a.m. EDT.